Apart from cancer, ATX-LPAR1 combination therapy or dual inhibitors of ATX and LPAR1 could also be used to treat IPF, where this signaling pathway has major implications in driving fibrosis. This evidence concerns the gene LPAR1 and idiopathic pulmonary fibrosis.